Clinical Trial Update: Glucagon-like Peptide-2 Mediated Secretion of Stored Enteral Lipids [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 clinical trial investigating glucagon-like peptide-2 mediated secretion of stored enteral lipids for hyperlipidemias has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperlipidemias

Snippet

Sponsor: University Health Network, Toronto | Conditions: Hyperlipidemias | Phase 2, Phase 3 | Status: COMPLETED